NCT00066326View on ClinicalTrials.gov

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

September 30, 2005

Conditions
Leukemia
Interventions
DRUG

imatinib mesylate

DRUG

tanespimycin

Trial Locations (1)

48201-1379

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00066326 - Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter